Almirall Advances LAD603 from Phase 1 Completion to Phase 2 Trial for Severe Alopecia Areata
Key Insights
Almirall S.A. recently completed a Phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of LAD603 in healthy adult subjects.
The company has now initiated a Phase 2 randomized, placebo-controlled, double-blind trial to evaluate LAD603's efficacy and safety in adults with severe to very severe alopecia areata (search).
The Phase 2 study tests three dose levels of the subcutaneous injectable drug against placebo over 28 weeks, aiming to find the optimal balance of hair regrowth and safety.
Almirall S.A. has successfully completed a Phase 1 clinical study of LAD603 and advanced the investigational subcutaneous drug into Phase 2 testing for severe alopecia areata (search), marking a significant milestone in the company's dermatology pipeline expansion.
Phase 1 Study Completion Sets Foundation
The completed Phase 1 study was designed as a randomized, 2-part, single-blind, placebo-controlled trial evaluating single and multiple ascending doses of LAD603 in healthy adult subjects. The study assessed safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of the subcutaneous drug. The trial began on December 22, 2023, and reached primary completion with updates submitted as recently as December 16, 2025.
The Phase 1 research was conducted as a randomized and sequential study with no masking, meaning participants and researchers were aware of the treatment settings. Participants received varying doses of LAD603 alongside a placebo comparator, with the primary goal of establishing a safety profile before progressing to later trial phases.
Phase 2 Trial Targets Severe Alopecia Areata
Building on the Phase 1 results, Almirall has initiated a Phase 2 randomized, placebo-controlled, double-blind clinical study titled "A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata (search)." The trial was first submitted on December 29, 2025, and is currently recruiting participants.
The Phase 2 study tests LAD603 as an injectable drug administered under the skin against a matching placebo injection. Participants receive one of three dose levels of LAD603 or placebo over 28 weeks. The study aims to determine which dose provides the optimal balance of hair regrowth and safety while establishing whether the drug offers clear benefits over placebo treatment.
Study Design and Clinical Significance
The Phase 2 trial employs an interventional design where participants are randomly assigned to LAD603 or placebo in parallel groups treated simultaneously. Both patients and investigators remain blinded to treatment assignments to reduce bias. The study's primary purpose is treatment-focused: proving that LAD603 works better than placebo for severe alopecia areata (search) while maintaining acceptable side effects.
This research addresses a significant unmet medical need, as alopecia areata (search) is described as "a visible and emotionally heavy condition with limited treatment choices." The advancement of LAD603 into Phase 2 testing represents an important step toward potentially providing patients with a new therapeutic option for this challenging condition.
Pipeline and Market Implications
The progression from Phase 1 completion to Phase 2 initiation expands Almirall's dermatology pipeline into what is characterized as "a high-visibility, consumer-facing disease." This development positions the company in the competitive landscape against other players advancing JAK inhibitors and biologics for immune-driven hair loss.
The Phase 2 trial timeline follows typical patterns for this phase of development, with readouts expected 18-30 months after start, depending on enrollment speed. Primary completion and final completion dates have not yet been posted, but the study is actively recruiting and recently updated on the ClinicalTrials.gov portal.